Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158527 | 0.93 | HTT (0.39) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL3158482 | 0.92 | HTT (0.38) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL7862024 | 0.89 | KDM4E (0.34) | MAPTKDM4EMEN1KMT2ANPC1 | |
| SCHEMBL3166254 | 0.89 | HPGD (0.35) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL3163518 | 0.87 | MAPT (0.37) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL3153612 | 0.82 | HTT (0.40) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL5615531 | 0.82 | ALDH1A1 (0.43) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL3166977 | 0.80 | KDM4E (0.39) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL3157828 | 0.80 | KDM4E (0.39) | SMN1; SMN2HTTMAPTKDM4EMEN1 | |
| SCHEMBL5615321 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423387-B1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INT (FR) | 2010-03-17 | — | — | EP | disclosed |
| US-6939007-B2 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2005-09-06 | — | — | US | disclosed |
| US-6747145-B2 | COUPLING A PROPARGYL ALCOHOL WITH A NAPHTHOL IN THE PRESENCE OF A CATALYTIC AMOUNT OF AN ACID, A SOLVENT AND 3 ANGSTROM MOLECULAR SIEVE TO GENERATE NAPHTHOPYRAN COMPOUND | JOHNSON & JOHNSON VISION CARE, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1423387-A1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2004-06-02 | — | — | EP | disclosed |
| US-20040084660-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2004-05-06 | — | — | US | disclosed |
| US-20030078441-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2003020718-A1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078441-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | CRY1, NQO1, G6PD | SMN1; SMN2 3433/4885HTT 569/4885MAPT 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.